Stockscreener 앱 받기
1.58
3.95%
0.06
시간 외 거래:
1.58
전일 마감가:
$1.52
열려 있는:
$1.52
하루 거래량:
31,460
Relative Volume:
2.05
시가총액:
$84.49M
수익:
$118.18M
순이익/손실:
$5.99M
주가수익비율:
11.98
EPS:
0.1319
순현금흐름:
$-12.91M
1주 성능:
+1.94%
1개월 성능:
+3.95%
6개월 성능:
-8.42%
1년 성능:
-31.30%
1일 변동 폭
$1.49
$1.59
1주일 범위
$1.48
$1.59
52주 변동 폭
$1.17
$2.62
Intercure Ltd Stock (INCR) Company Profile
INCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
1.58 | 84.49M | 118.18M | 5.99M | -12.91M | 0.1319 |
|
ZTS
Zoetis Inc
|
147.37 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.53 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.31 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.12 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-05-18 | 업그레이드 | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd 주식(INCR)의 최신 뉴스
What analysts say about InterCure Ltd. stockFree Stock Selection - PrintWeekIndia
What drives InterCure Ltd. stock priceFree Predictions - PrintWeekIndia
Is InterCure Ltd. a good long term investmentHigh-impact stock picks - jammulinksnews.com
InterCure Ltd. Stock Analysis and ForecastPowerful market insights - jammulinksnews.com
InterCure (NASDAQ:INCR) Shares Down 3.5% – Here’s What Happened - Defense World
What makes InterCure Ltd. stock price move sharply2x Return Forecast - newser.com
How InterCure Ltd. stock performs during market volatilityFree Access to Community - Newser
Why InterCure Ltd. stock attracts strong analyst attentionSmart Money Signals - Newser
InterCure (NASDAQ:INCR) Stock Price Up 1.9% – What’s Next? - Defense World
InterCure And Cookies Successfully Launch Flagship Pharmacy In Be'er Sheva, Israel - Barchart.com
InterCure (NASDAQ:INCR) Shares Down 4.4% – What’s Next? - Defense World
InterCure Reports FY2024 Results - mg Magazine
InterCure Reports Strong Start to 2025 Amid Recovery Efforts - TipRanks
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - PR Newswire
Intercure Ltd. Delays Yearly Report Filing - TipRanks
Interbusiness, Virdis partner to distribute Intercure products - Rubber News
InterCure (NASDAQ:INCR) Stock Price Down 3.4% – Time to Sell? - Defense World
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - GuruFocus.com
InterCure (NASDAQ:INCR) Shares Down 0.7%What's Next? - MarketBeat
InterCure Announces Leadership Change and Secures $18.2 Million Financing - TipRanks
InterCure Secures Massive $48M War Recovery Fund: CEO Takes Helm in Strategic Leadership Shift - Stock Titan
Short Interest in InterCure Ltd. (NASDAQ:INCR) Expands By 96.2% - MarketBeat
Jane Street Group LLC Acquires New Stake in InterCure Ltd. (NASDAQ:INCR) - Defense World
InterCure (NASDAQ:INCR) Trading Up 3.7% – Should You Buy? - Defense World
Cannabis co InterCure raising NIS 66m for Nir Oz facilityGlobes - Globes - Israel Business News
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - PR Newswire
Synbiotic's CAGR Forecast at 80%, ECS Botanics to Expand Footprint in Germany, & More from Intercure - Business of Cannabis -
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
InterCure nears break even in first half of 2024, despite ongoing Israel-Hamas war - Crain's Chicago Business
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewswire
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Yahoo Finance
IM Cannabis Merger Scrapped, Cel AI Gets a New CEO, & More from Intercure - Business of Cannabis
Analyst: Israel’s InterCure paving path to big gains - Green Market Report
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference - Business Wire
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million - Business Wire
InterCure: Bargain Israel Cannabis Play (NASDAQ:INCR) - Seeking Alpha
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint - Business Wire
InterCure Provides Update Regarding Nir Oz Facility in Israel - Cannabis Business Times
InterCure Provides an Update Regarding Nir Oz Facility - GlobeNewswire
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain - GlobeNewswire
InterCure Wins Cannolam Arbitration Proceeding - Yahoo Finance
InterCure Ltd Issues Update Regarding the Security Situation in Israel By Investing.com - Investing.com UK
Intercure Ltd (INCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.68%
자본화:
|
볼륨(24시간):